| Title | Author(s) | Year | View Count |
 | World gastroenterology organisation practice guideline - hepatitis B September 2008 | Heathcote, J; Abbas, Z; Alberti, A; Benhamou, Y; Chen, C; Elewaut, A; Ferenci, P; Hui, C; Isakov, V; Janssen, H; Lau, G; Lira, S; Okanoue, T; OnoNita, S; Piratvisuth, T; Rizzetto, M; Sollano, I; Pearman, W; Yeh, CT; Yuen, M; Krabshuis, J | 2009 | 44 |
 | 76 week follow up of HBeAg-positive chronic hepatitis B patients treated with telbivudine, adefovir or switched from adefovir to telbivudine | Marcellin, P; Chan, HLY; Lai, CL; Cho, M; Moon, YM; Chao, YC; Heathcote, J; Myers, R; Harb, G; Brown, NA | 2007 | 117 |
| Efficacy of telbivudine vs lamivudine at 2 years in patients with hbeag-positive chronic hepatitis B who are eligible for treatment based on guidelines | Rasenack, J; Poynard, T; Lai, CL; Gane, E; Brown, NA; Heathcote, J | 2007 | 144 |
| Optimal virologic and clinical efficacy at one year is associated with maximal early HBV suppression in nucleoside-treated hepatitis B patients | Zeuzem, S; Lai, CL; Gane, E; Liaw, YF; Thongsawat, S; Wang, YM; Chen, Y; Heathcote, J; Rasenack, J; Bzowej, N; Naoumov, N; Chao, G; Fielman, B; Brown, N | 2006 | 117 |
| A randomized trial of telbivudine (LDT) vs. adefovir for HBeAg-positive chronic hepatitis B: Results of the primary week 24 analysis | Chan, HLY; Lai, CL; Cho, M; Heathcote, J; Moon, Y-M; Chao, Y-C; Myers, R; Minuk, G; Marcellin, P; Jeffers, L; Sievert, W; Kaiser, R; Chao, G; Brown, N | 2006 | 123 |
| Phase III comparison of telbivudine vs lamivudine in HBeAg-positive patients with chronic hepatitis B: Efficacy, safety, and predictors of response at 1 year | Gane, E; Lai, CL; Liaw, YF; Thongsawat, S; Wang, YM; Cheng, Y; Heathcote, J; Rasenack, J; Bzowej, N; Naoumov, N; Chao, G; Fielman, B; Brown, N | 2006 | 120 |
| Phase III Comparison of Telbivudine vs Lamivudine in Patients with Chronic Hepatitis B: Efficacy, Safety, and Predictors of Response at 1 Year | Bzowej, N; Lai, CL; Gane, E; Liaw, Y; Thongsawat, S; Wang, Y; Chen, Y; Heathcote, J; Rasenack, J; Naoumov, N; Chao, G; Fielman, B; Brown, N | 2006 | 117 |
| Telbivudine (LdT) vs. lmivudine for chronic Hepatitis B: First-year results from the international phase III GLOBE trial | Lai, CL; Gane, E; Liaw, YF; Thongsawat, S; Wang, YM; Chen, Y; Heathcote, J; Rasenack, J; Bzowej, N; Naoumov, N; Chao, G; Fielman, B; Brown, N; and the GLOBE Study Group, . | 2005 | 154 |
| Maximal early HBV suppression is predictive of optimal virologic and clinical efficacy in nucleoside-treated hepatitis B patients: scientific observations from a large multinational trial (the GLOBE study) | Lai, CL; Gane, E; Liaw, YF; Thongsawat, S; Wang, YM; Chen, Y; Heathcote, J; Rasenack, J; Bzowej, N; Naoumov, N; Chao, G; Fielman, B; Brown, N; and the GLOBE Study Group, . | 2005 | 153 |
| 5-year Follow-up of 998 Chronic Hepatitis B Patients to Determine Long-term Safety of Lamivudine and clinical Consequences of Lamivudine-Resistant Mutations | Lok, AS; Lai, CL; Leung, N; Yao, GB; Cui, ZY; Schiff, ER; Dienstag, JL; Heathcote, J; Little, NR; Griffiths, DA; Gardner, SD; Castiglia, M | 2003 | 107 |
|
